Advertising Analysis Review Source: Advertising Analysis Report, November 2007 Advertised Drug Classes Top1 January-November 2007 Angiotensin II antagonists \$5,914,200 (+36%) **Cholesterol reducers** \$5,650,600 (-11%) Antiasthmatics/bronchodilators \$5,157,600 (+6%) **COX-2** inhibitors \$5,086,100 (+274%) **Analgesics-narcotics** \$3,428,300 (+37%) \$3,315,700 (+6%) **Diabetes diagnosis and therapy** Vaccines **\$2,667,000** (+64%) \$2,613,500 (-27%) Ulcer therapy Contraceptives \$1,757,500 (-28%) Anti-allergy/rhinitis therapy \$1,641,000 (+82%) ercial Distribution Advertised Froducts Тор uthorised users can download, anuary-November opy for personal use Pre ige \$3,739,100 (+999%) \$2,476,100 (+3%) Cres or \$2,243,800 (+599%) Alveso Lipitor \$1,844,200 (-6%) \$1,764,800 (+17%) Avapro Lyrica \$1,575,300 (+15%) Symbicort Smart \$1,373,300 (+999%) \$1,347,000 (-%) Celebrex Micardis \$1,309,900 (+325%) To find out more Nexium \$1,233,700 (+5%) about СРМ these figures, contact your STA representa tive:

Canadian Pharmaceutical Marketing / February 2008

John Donnet (514) 695-